公开(公告)号：US12104191B2

公开(公告)日：2024-10-01

申请号：US17823853

申请日：2022-08-31

Applicant: ZHEJIANG UNIVERSITY OF TECHNOLOGY

Inventor： Yaping Xue ,  Shuping Zou ,  Zhentao Jiang ,  Jianmiao Xu ,  Feng Cheng ,  Yuguo Zheng

IPC: C12P13/00 ,  C07K14/245 ,  C12N1/21 ,  C12N9/00 ,  C12N9/04 ,  C12N9/06 ,  C12N9/10 ,  C12N9/12 ,  C12N15/10 ,  C12N15/52 ,  C12N15/70

CPC classification number: C12P13/001 ,  C07K14/245 ,  C12N9/0006 ,  C12N9/0016 ,  C12N9/1077 ,  C12N9/1205 ,  C12N9/1241 ,  C12N9/93 ,  C12N15/1082 ,  C12N15/52 ,  C12N15/70 ,  C12Y101/01119 ,  C12Y104/01002 ,  C12Y204/02011 ,  C12Y207/01086 ,  C12Y207/07018 ,  C12Y603/01005 ,  C12N2800/101

Abstract: A cofactor self-sufficient Escherichia coli and its construction method and application in the synthesis of L-glufosinate are provided. The present invention expresses a NADH kinase and key enzymes of the cofactor synthesis pathway in E. coli, and knocks out the genes of enzymes that catabolizes cofactor, and with the addition of co-metabolic intermediates during cell incubation, the intracellular NADP(H) concentration is increased by at least 50% and the catalytic activity of glufosinate dehydrogenase by 2-fold, resulting in a significant increase in the spatiotemporal yield of the glufosinate synthesis reaction.

公开(公告)号：US20240060104A1

公开(公告)日：2024-02-22

申请号：US18269694

申请日：2021-04-26

Applicant: DAESANG CORPORATION

Inventor： Jong Yun HAN ,  Chel Min YANG ,  Yong Soo KIM ,  Young Il JO

IPC: C12P17/10 ,  C12N9/10

CPC classification number: C12P17/10 ,  C12N9/1077 ,  C12R2001/19 ,  C12Y204/02017

Abstract: The present invention relates to an E. coli hisG-derived ATP-phosphoribosyltransferase variant having a reduced feedback inhibition by histidine and a strain expressing the same. The variant may maintain its activity even at a high histidine concentration, thus increasing histidine production.

公开(公告)号：US11898174B2

公开(公告)日：2024-02-13

申请号：US17555012

申请日：2021-12-17

Applicant: Codexis, Inc.

Inventor： Jonathan Vroom ,  Jessica Anna Hurtak ,  Anders Matthew Knight

IPC: C12N9/10

CPC classification number: C12N9/1077 ,  C12Y204/02003

Abstract: The present invention provides engineered uridine phosphorylase (UP) enzymes, polypeptides having UP activity, and polynucleotides encoding these enzymes, as well as vectors and host cells comprising these polynucleotides and polypeptides. Methods for producing UP enzymes are also provided. The present invention further provides compositions comprising the UP enzymes and methods of using the engineered UP enzymes. The present invention finds particular use in the production of pharmaceutical compounds.

公开(公告)号：US11793860B2

公开(公告)日：2023-10-24

申请号：US16991780

申请日：2020-08-12

Applicant: The Regents of the University of California ,  The United States Government as Represented by the Department of Veterans Affairs

Inventor： Leonard H. Rome ,  Valerie Ann Kickhoefer ,  Steven M. Dubinett ,  Sherven Sharma ,  Upendra K. Kar

IPC: A61K38/19 ,  C07K14/52 ,  A61K47/69 ,  A61K38/00 ,  A61K38/45 ,  C12N9/10 ,  A61K35/12 ,  A61K48/00 ,  C07H21/00 ,  C07K7/06 ,  C07K14/47 ,  C12N5/0783 ,  C12N9/96 ,  C12N15/86 ,  G01N33/535

CPC classification number: A61K38/195 ,  A61K38/00 ,  A61K38/45 ,  A61K47/6921 ,  C07K14/521 ,  C12N9/1077 ,  C12Y204/0203 ,  A61K35/12 ,  A61K48/00 ,  C07H21/00 ,  C07K7/06 ,  C07K14/47 ,  C07K2319/00 ,  C07K2319/01 ,  C12N5/0636 ,  C12N9/96 ,  C12N15/86 ,  G01N33/535

Abstract: The invention relates to compositions of vault complexes containing recombinant cytokine fusion proteins that include a cytokine and a vault targeting domain, and methods of using the vault complexes to deliver the cytokines to a cell or subject, and methods for using the compositions to treat cancer, such as lung cancer.

公开(公告)号：US11692178B2

公开(公告)日：2023-07-04

申请号：US17351369

申请日：2021-06-18

Applicant: ZHEJIANG ZHENYUAN BIOTECH CO., LTD. ,  Tianjin University of Science and Technology

Inventor： Xixian Xie ,  Weiming Fan ,  Heyun Wu ,  Wei Jiang ,  Daoguang Tian ,  Yanna Chen ,  Yue Zhang ,  Jianqing Tu

IPC: C12N9/10 ,  C12N9/06 ,  C12P13/24 ,  C07K14/245

CPC classification number: C12N9/1077 ,  C07K14/245 ,  C12N9/0016 ,  C12P13/24 ,  C12Y104/01003 ,  C12Y204/02017

Abstract: A genetically engineered bacterium includes a genome of the Eschericia coli and a mutant encoding gene hisG* of a Corynebacterium glutamicum ATP phosphoribosyl transferase HisG on the genome, and the gene hisG* is strongly expressed to enhance activity of a key enzyme HisG for histidine synthesis. The gene hisG* has a nucleotide sequence as shown in SEQ ID NO: 1; a copy number of histidine operon genes hisDBCHAFI of the Eschericia coli is further increased on the genome to enhance a terminal synthetic route of histidine; an encoding gene lysE from an arginine/lysine transportprotein of the Corynebacterium glutamicum is further integrated to the genome and strongly expressed to promote the intracellular histidine secrete to the extracellular space; and an encoding gene rocG of glutamate dehydrogenase of Bacillus subtilis is further integrated to the genome and strongly expressed to promote generation of histidine.

公开(公告)号：US11661616B2

公开(公告)日：2023-05-30

申请号：US16638974

申请日：2019-03-27

Applicant: CJ CHEILJEDANG CORPORATION

Inventor： Ji Yeon Lee ,  Jin Sook Chang ,  Hyung Joon Kim ,  Byoung Hoon Yoon ,  Sun Hyoung Choi ,  Yunjung Choi

IPC: C12N9/10 ,  C12P13/04 ,  C12N9/14 ,  C12P13/14 ,  C12N15/77 ,  C12N1/20

CPC classification number: C12P13/04 ,  C12N1/20 ,  C12N9/1077 ,  C12N9/14 ,  C12N15/77 ,  C12P13/14 ,  C12Y204/02017 ,  C12Y306/01031 ,  C12N2830/55

Abstract: The present disclosure relates to a microorganism having increased glycine productivity and a method for producing a fermented composition using the microorganism, and more specifically, to a microorganism of the genus Corynebacterium having increased glycine productivity due to the introduction of a mutation in HisG, a method for preparing a fermented composition comprising glycine and glutamic acid using the microorganism of the genus Corynebacterium, and the fermented composition.

公开(公告)号：US20180258146A1

公开(公告)日：2018-09-13

申请号：US15973715

申请日：2018-05-08

Applicant: GLAXOSMITHKLINE BIOLOGICALS S.A.

Inventor： Normand BLAIS ,  Philippe Marc Helene DEHOTTAY ,  Marianne DEWERCHIN ,  Philippe GOFFIN ,  Denis MARTIN

IPC: C07K14/34 ,  C12N9/10

CPC classification number: C07K14/34 ,  C07K1/00 ,  C07K2319/034 ,  C12N9/1077 ,  C12Y204/02036

Abstract: Methods for producing a conjugate of a bacterial toxin, including diphtheria toxin or CRM197, are provided.

公开(公告)号：US20180110777A1

公开(公告)日：2018-04-26

申请号：US15557393

申请日：2016-03-18

Applicant: The Johns Hopkins University

Inventor： Carol W. Greider ,  Stella S. Lee

IPC: A61K31/502 ,  C12Q1/6851 ,  C12Q1/686 ,  C12N9/10 ,  C12N9/12 ,  A61P7/00 ,  A61P7/06 ,  A61P11/00 ,  A61P35/00 ,  A61P17/00

CPC classification number: A61K31/502 ,  A61K31/4184 ,  A61K31/55 ,  A61K31/7105 ,  A61K31/711 ,  A61K31/713 ,  A61K45/06 ,  A61P7/00 ,  A61P7/06 ,  A61P11/00 ,  A61P17/00 ,  A61P35/00 ,  C12N9/1077 ,  C12N9/12 ,  C12N15/1137 ,  C12N15/86 ,  C12N2310/11 ,  C12N2310/14 ,  C12N2310/141 ,  C12N2310/3231 ,  C12N2310/531 ,  C12Q1/6851 ,  C12Q1/686 ,  C12Y204/0203 ,  C12Y207/11022 ,  A61K2300/00

Abstract: Provided herein are methods for increasing telomere length comprising contacting a cell with an agent that activates the ataxia telangiectasia mutated (ATM) kinase pathway or a cyclin dependent kinase pathway, thereby elongating telomeres in the cell. Also provided is a method for treating disorders such as cancer and telomere syndromes.

公开(公告)号：US09873743B2

公开(公告)日：2018-01-23

申请号：US15342668

申请日：2016-11-03

Applicant: Stemline Therapeutics, Inc.

Inventor： Ivan Bergstein

IPC: C12P21/02 ,  C07K16/28 ,  C12N9/10 ,  C12P21/06 ,  C12N15/64 ,  C12N5/16 ,  C07K14/705 ,  A61K39/395

CPC classification number: C07K16/2866 ,  A61K39/00 ,  C07K16/18 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2317/76 ,  C07K2317/92 ,  C07K2317/94 ,  C07K2319/55 ,  C12N5/163 ,  C12N9/1048 ,  C12N9/1077 ,  C12N15/86 ,  C12Y204/02036

Abstract: The present invention provides antibodies that bind to the IL-3 receptor alpha subunit alpha (Il3Rα) chain, and compositions comprising such antibodies. The present invention provides methods for inhibiting or reducing an IL3Rα-expressing cell population, the methods comprising contacting a population of IL3Rα-expressing cells (e.g., cancer cells and/or cancer stem cells) with an antibody that binds to IL3Rα. The present invention also provides antibody conjugates comprising an antibody that binds to an IL3Rα chain linked to a cytotoxic agent or anticellular agent and compositions comprising such conjugates. The present invention also provides methods for preventing, treating and/or managing a disorder associated with IL3Rα-expressing cells (e.g., a hematological cancer), the methods comprising administering to a subject in need thereof an antibody that binds to IL3Rα.

公开(公告)号：US09764006B2

公开(公告)日：2017-09-19

申请号：US14650699

申请日：2013-12-09

Applicant: The General Hospital Corporation

Inventor： Zhirui Wang ,  Christene A. Huang ,  David H. Sachs

IPC: C07K14/55 ,  C12N15/09 ,  C12N15/63 ,  A61K38/20 ,  A61K38/45 ,  A61K45/06 ,  C12N15/81 ,  C12N9/10 ,  C07K14/21 ,  A61K38/00

CPC classification number: A61K38/45 ,  A61K38/00 ,  A61K38/2013 ,  A61K45/06 ,  C07K14/21 ,  C07K14/55 ,  C07K2319/55 ,  C12N9/1077 ,  C12N15/09 ,  C12N15/63 ,  C12N15/815 ,  C12Y204/02036 ,  A61K2300/00

Abstract: IL-2 fusion toxins, e.g., bivalent-IL2 fusion toxins, and methods of use thereof.